A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis



Status:Recruiting
Conditions:Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - 70
Updated:1/27/2019
Start Date:November 20, 2018
End Date:December 2019
Contact:Cherie Robbins, BScN
Email:clinicaltrialsinfo@anaptysbio.com
Phone:858-362-6295

Use our guide to learn which trials are right for you!

A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis

A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple
doses of ANB019 in subjects with Palmoplantar Pustulosis (PPP)

This study is a Phase II, randomized, placebo-controlled, double-blind, multiple dose study
to evaluate the efficacy and safety, and PK of ANB019 in subjects with Palmoplantar
Pustulosis

Inclusion Criteria:

- Clinically confirmed diagnosis of PPP

- Disease duration of at least 6 months prior to screening

- Present with active pustules on palms or/and soles at screening

Exclusion Criteria:

- Any other ongoing inflammatory disease that interfere with the investigator's ability
to evaluate the subject's response to therapy

- History of recurrent or active/serious infection

- Ongoing use of psoriasis prohibited medication

Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
2
sites
Wilmington, North Carolina 28403
?
mi
from
Wilmington, NC
Click here to add this to my saved trials
Indianapolis, Indiana 46260
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials